
Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Ruyi He at 301-796-0910, (CDER) Thomas Moreno at 301-796-2247, or (CBER) Bruce Schneider at 301-827-8343.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**October 2007
Drug Safety**

Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation

Additional copies are available from:

*Office of Training and Communications
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
<http://www.fda.gov/cder/guidance/index.htm>*

or

*Office of Communication, Training, and
Manufacturers Assistance, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
(Tel) 800-835-4709 or 301-827-1800
<http://www.fda.gov/cber/guidelines.htm>*

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**October 2007
Drug Safety**

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND: HEPATOTOXICITY.....	2
III.	SIGNALS OF DILI AND HY'S LAW	3
IV.	CLINICAL EVALUATION OF DILI	6
A.	General Considerations	6
1.	<i>Patients with Liver Abnormalities or Disease</i>	<i>7</i>
2.	<i>Detection of DILI</i>	<i>7</i>
3.	<i>Confirmation</i>	<i>7</i>
4.	<i>Close Observation.....</i>	<i>8</i>
5.	<i>Decision to Stop Drug Administration.....</i>	<i>8</i>
6.	<i>Evaluating Data for Alternative Causes</i>	<i>9</i>
7.	<i>Follow-Up to Resolution.....</i>	<i>10</i>
8.	<i>Rechallenge.....</i>	<i>10</i>
9.	<i>Research Opportunities</i>	<i>11</i>
B.	Case Report Forms	12
C.	Interpretation of Signals of DILI or Acute Liver Failure	12
1.	<i>Frequency and Magnitude of Liver AT Abnormalities</i>	<i>12</i>
2.	<i>Combined Elevations of Aminotransferases and Bilirubin.....</i>	<i>13</i>
D.	Analysis of Signals of DILI.....	13
1.	<i>Assessment of Drug Metabolism.....</i>	<i>13</i>
2.	<i>Assessment of Liver-Related Adverse Events in Controlled Trials.....</i>	<i>14</i>
3.	<i>Assessment of Liver-Related Adverse Events in the Entire Clinical Trials Database</i>	<i>14</i>
4.	<i>Assessment of Hy's Law Cases in the Clinical Trials Database.....</i>	<i>14</i>
5.	<i>Overall Assessment of a Drug's Potential to Cause DILI</i>	<i>15</i>
	REFERENCES.....	17
	APPENDIX A: ILLUSTRATIVE EXAMPLES OF DILI.....	21

Guidance for Industry¹

Drug-Induced Liver Injury: Premarketing Clinical Evaluation

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance is intended to assist the pharmaceutical industry and other investigators who are conducting new drug development in assessing the potential for a drug² to cause *severe* liver injury (i.e., fatal, or requiring liver transplantation). In particular, the guidance addresses how laboratory measurements that signal the potential for such drug-induced liver injury (DILI) can be obtained and evaluated during drug development. This evaluation is important because most drugs that cause severe DILI do so infrequently; typical drug development databases with up to a few thousand subjects exposed to a new drug will not show any cases. Databases do, however, often show evidence of a drug's *potential* for severe DILI if the clinical and laboratory data are properly evaluated for evidence of lesser injury that may not be severe, but may predict the ability to cause more severe injuries. This guidance describes an approach that can be used to distinguish signals of DILI that identify drugs likely to cause significant hepatotoxicity from signals that do not suggest such a potential. This guidance does not address issues of preclinical evaluation for potential DILI, nor the detection and assessment of DILI after drug approval and marketing.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are

¹ This guidance has been prepared by the Division of Gastroenterology Products, the Office of Medical Policy, and the Office of Surveillance and Epidemiology in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA).

² This guidance uses the term *drug* or *product* to refer to all products, except whole blood and blood components, regulated by CDER and CBER, including vaccines, and uses the term *approval* to refer to both drug approval and biologic licensure.

Contains Nonbinding Recommendations

Draft — Not for Implementation

cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND: HEPATOTOXICITY

Hepatotoxicity has been the most frequent single cause of safety-related drug marketing withdrawals for the past 50 years (e.g., iproniazid), continuing to the present (e.g., ticrynafen, benoxaprofen, bromfenac, troglitazone, nefazodone). Hepatotoxicity discovered after approval for marketing also has limited the use of many drugs, including isoniazid, labetalol, trovafloxacin, tolcapone, and felbamate (Temple 2001). Several drugs have not been approved in the United States because European marketing experience revealed their hepatotoxicity (e.g., ibufenac, perhexiline, alpidem). Finally, some drugs were not approved in the United States because premarketing experience provided evidence of potential toxicity (e.g., dilevalol, tasosartan, ximelagatran). Although most significant hepatotoxins have caused predominantly hepatocellular injury, indicated by leakage of aminotransferase (AT) enzymes from injured liver cells without prominent evidence of hepatobiliary obstruction, the pattern of injury can vary. Many drugs cause cholestasis, but in general this condition is reversible after administration of the offending drug has stopped. Cholestatic injuries are less likely to lead to death or transplant, although there have been exceptions.

Drugs cause liver injuries by many different mechanisms. These injuries resemble almost all known liver diseases and there are no pathognomonic findings, even upon liver biopsy, that make diagnosis of DILI certain. Therefore, when possible DILI is suspected, it is essential to gather additional clinical and laboratory information, to observe the time course of the injury, and to seek alternative causes of the liver injury, such as acute viral hepatitis A, B, or C, autoimmune or alcoholic hepatitis, biliary tract disorders, and circulatory problems of hypotension or right heart congestive failure that may cause ischemic or hypoxic hepatopathy. It is also prudent to assess the subject for previously existing liver disease, such as chronic hepatitis C or nonalcoholic steatohepatitis (NASH), that may or may not have been recognized before exposure to the experimental drug.

Only the most overt hepatotoxins can be expected to show cases of severe DILI in the 1,000 to 3,000 subjects typically studied and described in a new drug application (NDA). Overtly hepatotoxic agents (e.g., carbon tetrachloride, chloroform, methylene chloride) are toxic to anyone receiving a large enough dose, and drugs that cause such predictable and dose-related injury generally are discovered and rejected in preclinical testing. More difficult to detect is toxicity that is not predictable or clearly dose-related, but seems to depend on individual susceptibilities that have, to date, not been characterized. Most of the drugs withdrawn from the market for hepatotoxicity have had rates of death or transplantation in the range of ≤ 1 per 10,000, so that a single case of such an event would not be reliably found even if several thousand subjects were studied. Cases of severe DILI have rarely been seen in drug development programs of significantly hepatotoxic drugs.

What are regularly seen during drug development are mild liver injuries, often laboratory signals without any symptoms. The problem is that both drugs capable of severe DILI and drugs that

Contains Nonbinding Recommendations

Draft — Not for Implementation

have a low potential for causing severe injury (e.g., aspirin, tacrine, heparin, hydroxyl-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (*statins*)) can generate these types of signals. Therefore, an approach is needed that can distinguish drugs likely to cause severe DILI from drugs unlikely to do so.

In general, the type of liver injury that leads to severe DILI is a predominantly hepatocellular injury. Hepatocellular injury is indicated by rises in serum AT activities reflecting release of alanine or aspartate aminotransferase (ALT or AST) from injured liver cells. The ability to cause some hepatocellular injury, however, is not a reliable predictor of a drug's potential for severe DILI. Many drugs that cause transient rises in serum AT activity do not cause progressive or severe DILI, even if drug administration is continued. It is only those drugs that cause hepatocellular injury extensive enough to affect the liver's functional ability to clear bilirubin from the plasma or to synthesize prothrombin and other coagulation factors that cause severe DILI. It is important to identify those drugs as rapidly as possible.

The drugs that have caused severe DILI in humans have not shown clear hepatotoxicity in animals, generally have not shown dose-related toxicity, and, as noted, generally have caused low rates of severe injury in humans (1 in 5,000 to 10,000 or less). These reactions thus appear to reflect host factors and individual susceptibility. Consequently, they have been termed *idiosyncratic*, meaning dependent upon the individual person's particular constitution. Whether they are the result of genetic or acquired differences has not yet been established, and to date no genetic, metabolic, or other characteristic has been found to predict severe DILI in an individual.

Some severe DILI examples have been different from the more commonly seen hepatocellular idiosyncratic type. Perhexiline, an anti-anginal drug marketed in Europe, produced toxicity within months that had the histological appearance of alcoholic cirrhosis (Pessayre and Biachara et al. 1979). Fialuridine caused modest acute liver injury, but most strikingly led to severe metabolic acidosis and multiorgan failure as mitochondrial oxidative capacity was obliterated over a period of months (Kleiner and Gaffey et al. 1997; Semino-Mora and Leon-Monzon et al. 1997). Valproic acid causes hyperammonemic encephalopathy even without notable rises in serum AT activities. Benoxaprofen (Oraflex) induced intrahepatic cholestasis that over many months led to significant, sometimes fatal, liver injury, especially in elderly patients (Taggart and Alderdice 1982).

Retrospective evaluation of earlier experiences, augmented by recent experience, lead us to believe that appropriate testing and analysis in premarketing studies may improve the early detection of drugs that can cause severe hepatocellular injury.

III. SIGNALS OF DILI AND HY'S LAW

Because hepatocellular injury (AT elevations) is caused both by drugs that rarely, if ever, cause severe DILI (e.g., aspirin, HMG-CoA reductase inhibitors, heparin) and drugs that do cause such injury, evidence of hepatocellular injury is a necessary, but not sufficient, indicator of a potential for severe DILI. The frequency of AT elevation is not a good indicator either, as drugs such as tacrine (not a cause of severe DILI) can cause AT elevations in as many as 50 percent of

Contains Nonbinding Recommendations

Draft — Not for Implementation

patients. The degree of AT elevation may be a better indicator of potential for severe DILI, but the most specific indicator is evidence of altered liver function.

As noted, a typical NDA or BLA database usually will not show any cases of severe DILI, even for a drug that can cause such injury. Many drugs, however, including both significant hepatotoxins and drugs that do not cause severe liver injury, cause laboratory evidence of hepatic injury, with leakage of liver enzymes and the appearance in blood of elevations in serum AT to levels of 3-, 5-, and greater times the upper limits of normal (ULN). Generally, ALT is considered a more liver-specific aminotransferase than AST, although it also occurs in many tissues (Green and Flamm 2002). The finding of a higher rate of such elevations in drug-treated subjects than in a control group is a sensitive signal of a potential to cause severe DILI, but it is not a very specific signal. A more specific signal of such potential is a higher rate of more marked peak AT elevations (10x-, 15xULN), with cases of increases >1,000 U/L causing increased concern. The single clearest (most specific) predictor found to date of a drug's potential for severe hepatotoxicity, however, is evidence of reduced overall liver *function* in one or more subjects, manifested by increased serum total bilirubin (TBL), in conjunction with AT elevation, not explained by any other cause, together with an increased rate of AT elevation in the overall study population compared to control.

Recognition of the importance of altered liver function, in addition to liver injury, began with Hyman Zimmerman's observation that drug-induced hepatocellular injury (i.e., aminotransferase elevation) accompanied by jaundice had a poor prognosis, with a 10 to 50 percent mortality from acute liver failure (in pretransplantation days) (Zimmerman 1978, 1999). The reason for this now seems clear. The liver has a large excess of bilirubin-excreting capacity; injury to hepatocytes sufficient to cause jaundice or near jaundice (i.e., a bilirubin >2 mg/dL) represents an extent of damage so great that recovery may not be possible in some patients. Zimmerman's observation that hepatocellular injury sufficient to impair bilirubin excretion was ominous has been used at the Food and Drug Administration (FDA) over the years to identify drugs likely to be capable of causing severe liver injury, as distinct from drugs that cause lesser hepatocellular injury (i.e., AT elevation without bilirubin elevation) but are not as likely to cause severe injury (e.g., aspirin, tacrine, heparin). The observation of the critical importance of altered liver function has been referred to informally as *Hy's Law* (Temple 2001; Reuben 2004).

Briefly, Hy's Law cases have the following three components:

1. The drug causes hepatocellular injury, generally shown by more frequent 3-fold or greater elevations above the ULN of ALT or AST than the (nonhepatotoxic) control agent or placebo.
2. Among subjects showing such AT elevations, often with ATs much greater than 3xULN, some subjects also show elevation of serum TBL to >2xULN, without initial findings of cholestasis (serum alkaline phosphatase (ALP) activity >2xULN).
3. No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury.

Contains Nonbinding Recommendations

Draft — Not for Implementation

Finding one Hy's Law case in clinical trials is ominous; finding two is highly predictive of a potential for severe DILI. Clinical trials of the beta blocker dilevalol (enantiomer of labetalol, a diastereoisomeric mixture), showed two such cases in about 1,000 exposures. The drug was not approved in the United States, and examination of a postmarketing study in Portugal revealed fatal liver injury. Clinical trials of tasosartan, an angiotensin II blocking agent, showed a single Hy's Law case. The manufacturer was asked to do a large-scale safety study before the drug could be approved. The study was never conducted.

As a rule of thumb, based on Zimmerman's original estimate of 10 to 50 percent mortality associated with hepatocellular injury sufficient to impair the liver bilirubin excretory function, severe DILI can be estimated to occur at a rate of at least one-tenth the rate of so-called Hy's Law cases (Temple 2001). This observation was recently confirmed in large studies of DILI in Spain (Andrade and Lucena et al. 2005) and in Sweden (Björnsson and Olsson 2005) in which approximately 10 percent of subjects with hyperbilirubinemia or jaundice died or needed liver transplants.

Recent examples of some drugs causing idiosyncratic hepatotoxicity (e.g., bromfenac, troglitazone, ximelagatran) further illustrate the predictive value of Hy's Law, where findings during clinical trials were noted and severe DILI occurred after marketing. These examples are described in detail in Appendix A.

Past experience, including the three examples, shows that there is a set of laboratory abnormality signals that have the ability to predict a potential for severe DILI with reasonable sensitivity and specificity in a database of several thousand subjects. Although it is not yet possible to provide precise specificity and sensitivity estimates for the various signals, guidance can be provided on use of these major indicators of a potential for severe DILI, as follows:

- **An excess of AT elevations to >3xULN compared to a control group**

AT elevations to >3xULN are relatively common and may be seen in all groups, but an excess of these elevations compared to a control group is nearly always seen for drugs that ultimately prove severely hepatotoxic at relatively high rates (1/10,000). Therefore, the sensitivity of an excess of >3xULN AT elevations as a predictor of a potential for severe DILI is high. But many drugs show this signal without conferring a risk of severe injury (e.g., tacrine, statins, aspirin, heparin), indicating low specificity for an excess of AT elevations alone. There are no good data analyses at this time on how great this excess should be compared to control (e.g., 2-fold, 3-fold) to suggest an increased risk of DILI.

- **Marked elevations of AT to 5x-, 10x-, or 20xULN in smaller numbers of subjects in the test drug group and not seen (or seen much less frequently) in the control group**

Virtually all severely hepatotoxic drugs show such cases, indicating high sensitivity for predicting severe DILI, but, again, some drugs such as tacrine and others that are not severely hepatotoxic also can cause AT elevations to this degree, so that specificity of this finding is suboptimal.

Contains Nonbinding Recommendations

Draft — Not for Implementation

- **One or more cases of elevated bilirubin to >2xULN in a setting of pure hepatocellular injury (no evidence of obstruction, such as elevated ALP in gall bladder or bile duct disease, malignancy), with no other explanation (viral hepatitis, alcoholic or autoimmune hepatitis, other hepatotoxic drugs), accompanied by an overall increased rate of AT elevations >3xULN in the test drug group compared to placebo**

The sensitivity of this observation appears high for any given rate of severe DILI if enough people are exposed to the drug. Thus, if the true incidence of severe injury is 1/10,000, and the rate of Hy's Law cases is 1/1,000, about 3,000 subjects (*Rule of 3*) would be needed to have a 95 percent probability of observing a Hy's Law case in the treated population (Rosner 1995). The sensitivity of this finding appears very high if at least two cases are seen (e.g., dilevalol, bromfenac, troglitazone, ximelagatran). We are not aware of false positive Hy's Law findings. Therefore, the finding of two Hy's Law cases, and probably even one, is a strong predictor of a significant rate of severe liver injury. Failure to find a case, however, does not imply that a drug with AT elevations is free of a risk of severe DILI. The degree of assurance depends on the population exposed for a long enough time and on the rate of severe DILI that would be of interest.

The implications of these three findings may be different in patients with existing liver disease such as fatty liver disease, NASH, or chronic hepatitis C or B, with bilirubin metabolism abnormalities (Gilbert's syndrome), and in patients on drugs that treat liver disease or that inhibit bilirubin glucuronidation, such as indinavir or atazanavir (Zhang and Chando et al. 2005).

IV. CLINICAL EVALUATION OF DILI

A. General Considerations

For most drugs in development that reach phase 3 testing, the chances of encountering severe DILI are low. An increased frequency of mild hepatotoxicity (AT elevations) in early trials usually results in heightened screening to detect and evaluate liver injury during phase 3 testing. It is critical, however, to determine whether mild hepatotoxicity reflects a potential for severe DILI or reflects a capacity for only limited injury. To make this distinction, it is essential to detect any cases of more severe injury and to examine such cases closely, observing the course and outcome of the injury, and seeking additional information that might identify other causes. The following general recommendations for evaluating and monitoring potential drug-induced hepatotoxicity may not be suitable for all situations and should be modified for special populations, such as people with preexisting liver disease or malignancies, and in light of accumulating data. In addition, clinical trials of cellular and gene therapies and of vaccines pose specific challenges related to trial size and design, persistence of vectors, and tissue specificity. Applicants are encouraged to discuss these issues with the review division.

Contains Nonbinding Recommendations

Draft — Not for Implementation

1. Patients with Liver Abnormalities or Disease

Patients are sometimes excluded from clinical trials because of baseline liver test abnormalities or a history of liver disease, but there is no well-established reason to do this, except perhaps to avoid confusion between the previous disease and an effect of the test drug. These patients generally should be included in at least the phase 3 trials because they are likely to be treated with the drug if it is marketed. Preexisting liver disease is not known to make patients more susceptible to DILI (Zimmerman 1978, 1999), but it may be that a diminished *liver reserve* or the ability to recover could make the consequences of injury worse, making it appear that such patients were more susceptible to severe DILI. If the drug is intended to be prescribed or marketed to such patients after approval, they should be studied during controlled trials. It may be prudent, however, to first determine if DILI occurs in people with previously normal livers, before studying patients with well-characterized and stable chronic liver disease.

2. Detection of DILI

In general, early studies of a drug in study subjects with presumably normal liver function should involve obtaining liver tests every 2 to 4 weeks, at least for a few months. It is uncertain whether early symptoms (e.g., anorexia, nausea, fatigue, right upper abdominal discomfort, vomiting) precede or follow the first laboratory signs of hepatic injury (rising ALT, AST, or ALP) and the pattern of clinical and laboratory changes may vary with different drugs and recipients. In most cases, however, the first evidence of a problem is elevated AT or ALP. In longer trials, if there is no sign of liver injury after a reasonable length of exposure (e.g., 3 months), the monitoring interval can be increased to once every 2 to 3 months. Later trials also can use less frequent liver chemistry monitoring if there is no indication of hepatotoxicity.

If symptoms compatible with DILI precede knowledge of serum abnormalities, liver enzyme measurements should be made immediately, regardless of when the next visit or monitoring interval is scheduled. In some cases, symptoms may be an early sign of injury. Reliance on early symptoms, rather than serum enzyme monitoring, has become the standard for monitoring isoniazid therapy for prophylaxis of tuberculosis and seems to prevent severe liver injury if acted upon promptly (Nolan and Goldberg et al. 1999). Attention to symptoms does not supplant routine periodic assessment of AT, TBL, and ALP in trials of investigational drugs.

3. Confirmation

In general, an increase of serum AT to >3xULN should be followed by repeat testing within 48 to 72 hours of all four of the usual serum measures (ALT, AST, ALP, and TBL) to confirm the abnormalities and to determine if they are increasing or decreasing. There also should be inquiry about symptoms. Serum AT may rise and fall quite rapidly, and waiting a week or two before obtaining confirmation of elevations may lead to a false conclusion that the initially observed abnormality was spurious, or, of greater concern, to severe worsening if the initial abnormality was the herald of a severe reaction to follow. The need for prompt repeat testing is especially great if AT is much greater than 3xULN or TBL is greater than 2xULN. For outpatient studies, or studies in which subjects are far away from the study site, it may be difficult for the subjects to return to the study site promptly. In this case, the subjects should be retested locally, but

Contains Nonbinding Recommendations

Draft — Not for Implementation

normal laboratory ranges should be recorded, results should be made available to study investigators immediately, and the data should be included in the case reports. If symptoms persist or repeat testing shows AT >3xULN for the subjects with normal baseline measures or 2-fold increases above baseline values for subjects with elevated values before drug exposure, it is appropriate to initiate close observation to determine whether the abnormalities are improving or worsening.

4. Close Observation

Close observation is defined as follows:

- Repeating liver tests two or three times weekly. Frequency of retesting can decrease to once a week or less if abnormalities stabilize or study drug has been discontinued and subject is asymptomatic.
- Obtaining a more detailed history of symptoms and prior or concurrent diseases.
- Obtaining a history of concomitant drug use (including nonprescription medications, herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets.
- Obtaining a history of exposure to environmental chemical agents.
- Obtaining additional tests to evaluate liver function, as appropriate (e.g., International Normalized Ratio (INR)).
- Considering gastroenterology or hepatology consultation.

It is critical to initiate close observation immediately upon detection and confirmation of early signals of possible DILI, and not to wait until the next scheduled visit or monitoring interval. A threshold of a greater than 3xULN aminotransferase level is reasonable, as lesser elevations are common and nonspecific. If additional testing is done, beyond that specified in the study protocol, it is important that the subject's information be added to the case report forms or database.

5. Decision to Stop Drug Administration

It has been observed that *dechallenge* (stopping drug administration) does not always, or even usually, result in immediate improvement in abnormal lab values. Abnormal test values and symptoms may progress for several days or even weeks after discontinuation of the drug that caused the abnormality. For example, rising TBL usually follows serum AT increases by a few days to weeks. The primary goal of close observation is to determine as quickly as possible whether observed abnormal findings are transient and will resolve spontaneously or are progressive. For most DILI, no specific antidotes are available (except N-acetylcysteine for acute acetaminophen overdose if given promptly, and, possibly, intravenous carnitine for valproic acid hepatotoxicity). Promptly stopping administration of the offending drug usually is the only potentially effective therapy.

A difficult question is when to stop administration of the investigational drug. Because transient rises and falls of ALT or AST are common, and progression to severe DILI or acute liver failure is uncommon, automatic discontinuation of study drug upon finding a greater than 3xULN

Contains Nonbinding Recommendations

Draft — Not for Implementation

elevation of ALT or AST may be unnecessary. For most people, the liver appears capable of adapting to injury by foreign chemical substances, which may render a person tolerant to the drug despite continuation of exposure. Stopping a drug at the first hint of mild injury does not permit learning whether adaptation will occur, as it does for drugs such as tacrine that cause liver injury but do not cause severe DILI. On the other hand, continuing drug administration too long can be dangerous once there is marked transaminase elevation or evidence of *functional* impairment appearing after hepatocellular injury, as indicated by rising bilirubin or INR, which represent substantial damage. Although there is no published consensus on when to stop a drug in the face of laboratory abnormalities, and the decision will be affected by information on related drugs, the accumulating clinical experience, the nature of the patient, and many other factors, the following can be considered a basic guide. In general, treatment should be stopped if:

- ALT or AST >8xULN
- ALT or AST >5xULN for more than 2 weeks
- ALT or AST >3xULN **and** (TBL >2xULN **or** INR >1.5)
- ALT or AST >3xULN with the appearance of worsening of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia

6. Evaluating Data for Alternative Causes

One of the critical purposes of close observation is to gather additional clinical information to determine the most likely cause or causes of the observed abnormalities, and specifically, whether there is a cause other than the study drug, such as one of the following common causes. Other less common causes also may need to be considered.

- **Acute viral hepatitis.** The usual onset of hepatocellular DILI is indistinguishable from acute viral hepatitis A or B. Hepatitis C is much less often acute in its onset and tends to be insidious, but it sometimes can resemble acute drug injury. The presence of acute viral hepatitis A, B, and C should always be evaluated by serological markers. Viral hepatitis D (requires concomitant hepatitis B infection) and E are relatively rare in the United States. Hepatitis E is more common in developing countries, including Southeast Asia, and should be considered in recent travelers to those countries. Also rare is liver injury caused by Epstein-Barr virus and cytomegalovirus, although this is seen more commonly in immuno-suppressed individuals. Adolescent and young adult patients with possible DILI should be tested for Epstein-Barr virus. Hepatitis is common among transplant patients with CMV disease.
- **Alcoholic and autoimmune hepatitis.** Acute alcoholic hepatitis usually is recurrent, with a history of bingeing exposure to alcohol preceding episodes, and it has some characteristic features, such as associated fever, leukocytosis, right upper quadrant pain and tenderness, and AST >ALT, that may help distinguish it from other causes of liver injury. Autoimmune hepatitis may be acute or even fulminant in its onset; it does not always respond immediately to corticosteroids, but may have serological markers of value. Alcoholic and autoimmune hepatitis should be assessed by history and serologic testing (e.g., antinuclear antibodies).

Contains Nonbinding Recommendations

Draft — Not for Implementation

- **Biliary tract disorders.** Biliary tract disease more often causes cholestatic injury initially and should be investigated with gall bladder and ductal ultrasound study, especially if ALP is increased. Malignant interruption of the biliary tract also should be considered.
- **Cardiovascular causes.** Cardiovascular disease, especially right heart failure and hypotension, may cause acute centrilobular hypoxic cell necrosis (*ischemic hepatitis*) with spectacular increases of serum AT (e.g., AT >10,000). Cardiovascular dysfunction, including hypotension or right heart failure, should be assessed by physical examination and history.

Exclusion of the two ABCs (i.e., viral hepatitis A, B, or C; alcoholic or autoimmune hepatitis, biliary disorders, and circulatory disorders) as causes of liver injury should be attempted in all cases of suspected DILI, and the results should be recorded. There is a practical limit as to how much testing should be done to exclude less common liver diseases, such as acute Wilson's disease or alpha-1-antitrypsin deficiency.

It is also critical to discover concomitant treatment that might be responsible for injury. Many people take multiple drugs, perhaps less often in controlled clinical trials because of exclusion criteria, but subjects may not report taking disallowed drugs or other agents. The possible exposure to potentially toxic herbal or dietary supplement mixtures of unknown composition, nonprescription medications such as acetaminophen, or to occupational chemical agents may not be volunteered unless subjects are specifically questioned.

7. Follow-Up to Resolution

All study subjects showing possible DILI should be followed until all abnormalities return to normal or to the baseline state. DILI may develop or progress even after the causative drug has been stopped. Results should be recorded on the case report form and in the database. Note that still longer follow-up can sometimes reveal an off-drug repetition of what had appeared to be DILI, indicating that liver injury was related to an underlying liver disease.

8. Rechallenge

Whether or not to rechallenge a subject who showed mild DILI is a difficult question. Re-exposure may initiate a sometimes explosive and more severe reaction, as was observed with halothane several decades ago. Some cases of DILI show indicators of immunological reaction such as eosinophilia, rash, fever, or other symptoms or findings, and it is possible that such cases are more prone to recur with re-exposure. On the other hand, most people can adapt to xenobiotic substances such as new drugs and develop tolerance for them, as has been found even for drugs that can cause severe injury, such as isoniazid. The large majority of people showing hepatocellular injury on isoniazid recover fully or recover while continuing to take the drug, and some, but not all, can resume or continue taking the drug without further adverse consequence. If such tolerance develops, the use of rechallenge to verify drug causation would give a false negative result.

Contains Nonbinding Recommendations

Draft — Not for Implementation

Generally, rechallenge of subjects with significant ($>5\times\text{ULN}$) AT elevations should not be attempted. If such subjects are rechallenged, they should be followed closely. Rechallenge can be considered if the subject has shown important benefit from the drug and other options are not available or if substantial accumulated data with the test drug do not show potential for severe injury. The subject should be made aware of the potential risk, and consent to the rechallenge.

9. Research Opportunities

It is not known why only a few people show severe DILI in response to a hepatotoxic drug while others show nothing or seem to adapt. The current thinking is that there may be a genetic basis for such differences, but acquired factors may be equally important. The period of close observation provides a major opportunity to gather and store serial samples of blood and urine, to investigate characteristics of subjects who show evidence of mild or severe DILI, and to see how they differ from each other and from people who do not show any effects despite being similar in age, sex, and drug exposure. These serial samples can be studied by genomic, proteomic, and metabolomic methods to determine how subjects differ, and to seek biomarkers that identify the susceptible persons.

As part of the Critical Path Initiative,³ the FDA is working with industry, academia, and other experts to broaden our understanding of the biochemical and genetic bases of DILI. In June 2006, the FDA co-sponsored a scientific workshop to determine the feasibility of developing a mathematical (in-silico) model for DILI from which other predictive experimental models can be derived to characterize potential hepatotoxicity. The long-term goal is to develop a model, or models, that can help researchers identify criteria for determining when early clinical intervention (i.e., stopping the drug) is appropriate. It is also hoped that predictive bioassays and biomarkers can be identified that will help determine which patients most likely will suffer liver toxicity from specific compounds.

This urgently needed research is not a regulatory requirement, but is an important opportunity. At present, we are able only to search among patients with drug-induced injury to predict what might happen to others. Ideally, we should seek to identify individuals at increased risk before administering a drug that they cannot tolerate. The goal is to be able to identify persons who should never be exposed to a given drug because they are idiosyncratically hypersusceptible to, or unable to recover from, DILI caused by it. If tests that screen for people susceptible to severe DILI can be developed, a hepatotoxic drug could remain available to people who are not susceptible to severe DILI, instead of having to withdraw the drug from the market, allowing no one to benefit from it.

In addition, identification of common genotypic characteristics among patients experiencing DILI in response to one or more class-related hepatotoxic agents might permit the development of in vitro or ex vivo tests or genetically altered animal strains that can be used to better predict serious hepatotoxic potential, or the lack thereof, of new drugs belonging to the same or closely related classes.

³ See <http://www.fda.gov/oc/initiatives/criticalpath>.

Contains Nonbinding Recommendations

Draft — Not for Implementation

B. Case Report Forms

In addition to collecting information on laboratory abnormalities, clinical symptoms, and the potential cause of any hepatic illness, case report forms should include the following information for cases in which liver injury is found (including control subjects with such injury):

- Time and date from start of drug administration to start of illness
- Time and date of cessation of drug, or interruption of drug administration
- Space for recording free text to describe the course of illness, including abnormalities of aminotransferases, ALP, and TBL
- Risk factors, especially alcohol use history
- Use of all concomitant drugs (dose, start and stop dates, whether drug is known to be hepatotoxic, rechallenge and dechallenge information)
- Evaluation of nondrug causes: recent hepatitis A, B, and C serology, evidence for biliary obstruction, acute alcoholic hepatitis (AST >2xALT), recent history of severe hypotension or congestive heart failure, underlying other viral disease
- Rechallenge and dechallenge information with suspect drug, with details of time and dose
- All supplemental information, including tests in local laboratories, unscheduled tests and physical exam reports, consultation reports, narrative information, and special studies

Any potential Hy's Law case should be handled as a serious unexpected adverse event associated with the use of the drug and reported to the FDA promptly. Reporting should include all available information and should initiate a close follow-up until complete resolution of the problem and completion of all attempts to obtain supplementary data.

C. Interpretation of Signals of DILI or Acute Liver Failure

1. Frequency and Magnitude of Liver AT Abnormalities

The presence of even a single case of severe liver failure resulting from treatment in the premarketing clinical trials database is an indicator of a high level of hepatotoxic risk. More commonly, however, there will be no identifiable cases of severe liver injury, but rather varying degrees of serum AT abnormalities that need to be interpreted. As previously noted, slight abnormalities of this kind (to <3xULN) are common in untreated and placebo-treated subjects and are not informative about the potential for the development of severe DILI.

Therefore, it has become standard practice to look at greater deviations, such as AT values $\geq 3x$ -, $5x$ -, or $10x$ ULN. Because these abnormalities can occur in placebo-treated groups, it is important to compare their rate in drug-exposed subject groups relative to control groups (i.e., placebo or products that do not cause elevation of transaminases). An excess of AT abnormalities $>3x$ ULN is a signal of a potential for severe DILI, but, even though it has high sensitivity, it is not specific. Comparison of rates of AT elevations during drug treatment to a control group is probably less critical for abnormalities of greater magnitude (e.g., $10x$ ULN), as such elevations are rarely seen spontaneously. Therefore, these greater AT elevations can be examined in the whole clinical trials database, not just in the controlled trials. It should be appreciated that serum AT activity is a relatively volatile measurement, often rising and falling

Contains Nonbinding Recommendations

Draft — Not for Implementation

within days. It cannot be concluded from one measurement that a peak value has been seen, so that detection of an abnormal rise is a call for serial measures to determine which way the abnormality is moving, whether increasing or decreasing.

A number of factors may confound interpretation of AT abnormalities seen in NDA or BLA databases. Although the more extreme AT elevations may be better predictors of toxicity than smaller elevations, it is possible that close monitoring could affect the magnitude of abnormalities seen if it leads to earlier cessation of drug treatment that prevents the greater abnormalities from appearing. In addition, the contribution of drug treatment to an exacerbation of preexisting liver disease may be difficult to determine. Finally, normalization of abnormalities on continued treatment is not proof that the abnormality was not drug-caused, but may result from liver adaptation to the drug.

2. Combined Elevations of Aminotransferases and Bilirubin

When AT abnormalities indicating hepatocellular injury are accompanied by evidence of impaired hepatic function (bilirubin elevation $>2\times\text{ULN}$), in the absence of evidence for biliary obstruction (i.e., significant elevation of ALP) or some other explanation of the injury (e.g., viral hepatitis, alcohol hepatitis), the combined finding (i.e., Hy's Law cases) represents a signal of a potential for severe DILI. Experience has indicated that the occurrence of even one or two well-documented cases of this combination is ominous, indicating a likelihood that the drug will cause severe liver injury.

The absence of Hy's Law cases in an NDA or BLA database may allow an estimate of an upper limit of the rate for severe DILI, using the Rule of 3 derived from simple binomial calculation. There will be at least a 95 percent chance of seeing one or more cases of DILI in $3n$ study subjects if its true incidence is 1 in n subjects, and the group is well observed. Thus, if no cases of AT and bilirubin elevations are seen in 3,000 well-observed subjects, it can be concluded with 95 percent confidence that the true rate of such occurrences is not more than 1 per 1,000. This calculation would then suggest a rate of expected severe liver injury ≤ 1 per 10,000 exposed patients, assuming that the rate of severe injury when AT and TBL are both elevated is about 10 percent (Andrade and Lucena et al. 2005; Björnsson and Olsson 2005).

D. Analysis of Signals of DILI

Based on our experience, we recommend that the following analyses related to liver injury potential be carried out and included in an NDA or BLA, or included in an investigational new drug application when DILI is suspected and being evaluated.

1. Assessment of Drug Metabolism

The metabolism of a drug can have serious consequences for the safety profile of the drug. A drug may be metabolized to a hepatotoxic metabolite (e.g., acetaminophen, halothane, and isoniazid). Most hepatotoxic drugs have been oxidatively metabolized by the CYP450 system.

Contains Nonbinding Recommendations

Draft — Not for Implementation

Several in vitro methods are available to detect and quantify binding for a drug or its metabolites to liver proteins, including radiochemical and immunological methods.

2. Assessment of Liver-Related Adverse Events in Controlled Trials

Analysis of incidence rates of liver-related adverse events (abnormal AT, bilirubin, and ALP levels) seen in subjects in controlled trials with at least one dose of drug exposure should be provided, generally for pooled data, although study-to-study differences may be of interest. Rates can be given as the number of events per number of subjects exposed, or as the number of events per subject-years of exposure, preferably both. For many drugs, it appears that a minimum duration of exposure is required before DILI occurs. Therefore, it is useful to give the rates of liver-related adverse events for subjects who have had the minimum duration of exposure (e.g., rate in subjects with at least 1-month exposure). Rates for pooled data should include, but are not limited to:

- 3x-, 5x-, 10x-, and 20xULN elevations of AST, ALT, and either ALT or AST.
- Any elevations of bilirubin; elevated bilirubin to >1.5xULN, and to >2xULN.
- Any elevations of ALP >1.5xULN.
- Elevation of AT (>3xULN) accompanied by elevated bilirubin (>1.5xULN, >2xULN).
- Possibly liver-related deaths and liver-related treatment discontinuations. These cases should be described and time-to-event analyses should be performed. Follow-up status also should be provided. There should be a description of any histologic and rechallenge data.

All rates should be calculated separately for drug-, placebo-, and active-controlled groups. Normal ranges for all tests should be provided. Time-to-event analyses for elevated rates of significant individual events (e.g., elevated AT, bilirubin) should be provided. The contribution of sex, age, risk factors, and drug dose or regimen to the abnormalities seen should be explored.

3. Assessment of Liver-Related Adverse Events in the Entire Clinical Trials Database

Analysis of rates of liver-related adverse events (abnormal AT, bilirubin, and ALP levels) for the total clinical trials database, including subjects with exposure of at least one dose of study drug in phase 1 or phase 2 trials, or in uncontrolled, open label, extension trials should be provided. We recommend the same evaluation as for the controlled trials database discussed in section IV.D.2. Time-to-event analyses, mortality rates, study withdrawals, and similar data should be provided for significant abnormalities. The contribution of sex, age, and drug dose or regimen to the abnormalities seen should be explored.

4. Assessment of Hy's Law Cases in the Clinical Trials Database

NDA and BLA submissions should include a listing of possible Hy's Law cases identified by treatment group (e.g., subjects with any elevated AT of >3xULN, ALP <2xULN, and associated with an increase in bilirubin ≥ 2 xULN). A narrative summary for each Hy's Law case should be provided. Narrative summaries should not only provide, in text format, the data that are already

Contains Nonbinding Recommendations

Draft — Not for Implementation

presented in the case report tabulation, but also should provide a complete synthesis of all available clinical data and an informed discussion of the case, allowing for a better understanding of what the subject experienced. For a narrative summary to be useful, it should contain the following information:

- Subject's age, sex, weight, and height
- Discussion of signs and symptoms related to hepatotoxicity: type and timing
- Relationship of exposure duration and dose to the development of the liver injury
- Pertinent medical history
- Concomitant medications with dates and doses
- Pertinent physical exam findings
- Test results (e.g., laboratory data, biopsy data and reports, with dates and normal ranges)
- Time course of serum enzyme and bilirubin elevations
- A summary of all available clinical information including, if known:
 - Prior or current history of ethanol use
 - Evidence for pre- or co-existing viral hepatitis, or other forms of liver disease
 - Symptoms and clinical course including follow-up to resolution
 - Special studies, radiologic examinations, liver biopsy results
 - Presence or absence of possible confounders, including concomitant illness, use of concomitant medications that are known hepatotoxins, such as acetaminophen
- Discussion of hepatotoxicity as supported by available clinical data and overall assessment of treating physician, consultants, and applicants as to the likelihood of DILI
- Treatment provided
- Dechallenge and rechallenge results, if done
- Outcomes and follow-up information
- Copies of hospital discharge summaries, pathology and autopsy reports

The availability of liver biopsy, explant, or autopsy slides for pathology review by review staff or external expert consultants has been helpful in the FDA's assessment of such cases. Reports of external consultant opinions solicited by the applicant should be provided to the FDA.

Complete narrative summaries that include the components previously listed also should be provided for all subjects who died of hepatic illness, or who discontinued study drugs for hepatotoxicity, including subjects with abnormalities consistent with protocol-specific stopping rules.

5. Overall Assessment of a Drug's Potential to Cause DILI

The overall assessment should characterize a drug's potential for DILI and should consider at least the following questions:

- Was liver monitoring sufficiently frequent and thorough to characterize DILI risk?
- Were there any cases of probably drug-induced serious or severe DILI?
- Were there signals of a potential for DILI (e.g., AT elevations, Hy's Law cases) and how were these signals assessed?

Contains Nonbinding Recommendations

Draft — Not for Implementation

- What doses and durations of exposure were associated with hepatotoxicity signals?
- What approximate incidence of mild, moderate, and severe DILI could be expected postmarketing?
- Is the trial information sufficient to inform an overall risk-benefit assessment?
- Was there sufficient drug exposure (i.e., number of study subjects and duration of treatment of each study subject) and adequate liver test monitoring to reliably set an upper boundary for risk of severe DILI after marketing?
- What rate of severe injury (assuming Hy's Law cases occur at about 10 times the rate of severe injury) has been suggested or has been ruled out (e.g., no Hy's Law cases in 3,000 subjects implies a rate of such cases of $<1/1,000$ and thus a rate of severe DILI of $<1/10,000$)? This consideration should reflect the presence or absence of other signals, such as marked elevations of AT.
- Will some form of monitoring, by symptoms or serum testing, be needed? Usually, this would be considered only if there was evidence of severe liver injury or the potential for it. If so, effectiveness of monitoring in the NDA database should be discussed.

REFERENCES

- Andrade, RJ, MI Lucena, and MC Fernandez et al., 2005, Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period, *Gastroenterology*, 129(2):512-21.
- Björnsson, E and R Olsson, 2005, Outcome and Prognostic Markers in Severe Drug-Induced Liver Disease, *Hepatology*, 42(2):481-9.
- CDER, 1999, Medical Review of Troglitazone — Efficacy Supplement, NDA 20-720, Dr. Robert Misbin, http://www.fda.gov/cder/foi/nda/99/20720S12S14_Rezulin_medr_P1.pdf.
- CDER-PHRMA-AASLD Conference, 2000, clinical white paper, preconference study document before conference “Drug-Induced Liver Injury: A National and Global Problem,” <http://www.fda.gov/cder/livertox/clinical.pdf>.
- Dufour, DR, JA Lott, FS Nolte, DR Gretch, RS Koff, and LB Seeff, 2000, Diagnosis and Monitoring of Hepatic Injury I, Performance Characteristics of Laboratory Tests, *Clin Chem*, 46(12):2027-49.
- Dufour, DR, JA Lott, FS Nolte, DR Gretch, RS Koff, and LB Seeff, 2000, Diagnosis and Monitoring of Hepatic Injury II, Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring, *Clin Chem*, 46(12):2050-68.
- Fontana, RJ, TM McCashland, KG Benner, HD Appelman, NT Gunartanam, JL Wisecarver, JM Rabkin, and WM Lee, 1999, Acute Liver Failure Associated with Prolonged Use of Bromfenac Leading to Liver Transplantation, *Liver Transpl Surg*, 5(6):480-4.
- Gelperin, K, Risk Management of Hepatotoxic Drugs, <http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4069T1.pdf>, pp. 282-301.
- Gitlin, N, NL Julie, CL Spurr, KN Lim, and HM Juarbe, 1998, Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone, *Ann Intern Med*, 129(1):36-8.
- Goldkind, L and L Laine, 2006, A Systematic Review of NSAIDS Withdrawn from the Market Due to Hepatotoxicity: Lessons Learned from the Bromfenac Experience, *Pharmacoepidemiol Drug Saf*, 15(4):213-20.
- Graham, DJ, CR Drinkard, D Shatin, Y Tsong, and M Burgess, 2001, Liver Enzyme Monitoring in Patients Treated with Troglitazone, *JAMA*, 286(7):831-3.
- Graham, DJ, L Green, JR Senior, and P Nourjah, 2003a, Troglitazone-Induced Liver Failure: A Case Study, *Am J Med*, 114(4):299-306.

Contains Nonbinding Recommendations

Draft — Not for Implementation

- Graham, DJ, CR Drinkard, and D Shatin, 2003b, Incidence of Idiopathic Acute Liver Failure and Hospitalized Liver Injury in Patients Treated with Troglitazone, *Am J Gastroenterol*, 98(1):175-9.
- Green, RM and S Flamm, 2002, AGA Technical Review on the Evaluation of Liver Chemistry Tests, *Gastroenterology*, 123(4):1367-84.
- He, R, 2004, Clinical Review of Exanta (ximelagatran) Tablets, FDA Cardiovascular and Renal Drugs Advisory Committee Briefing Information, http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_04_FDA-Background-MOR-180.pdf.
- Herrine, SK and C Choudary, 1998, Severe Hepatotoxicity Associated with Troglitazone, *Ann Intern Med*, 130(2):163-4.
- Hunter, EB, PE Johnston, G Tanner, CW Pinson, and JA Awad, 1999, Bromfenac (Duract) — Associated Hepatic Failure Requiring Liver Transplant, *Am J Gastroenterol*, 94(8):2299-301.
- Kaplowitz, N, 2006, Rules and Laws of Drug Hepatotoxicity, *Pharmacoepidemiol Drug Saf*, 15(4):231-3.
- Kleiner, DE, MJ Gaffey, R Sallie, M Tsokos, L Nichols, R McKenzie, SE Strauss, and JH Hoofnagle, 1997, Histopathologic Changes Associated with Fialuridine Hepatotoxicity, *Mod Pathol*, 10(3):192-9.
- Knowler, WC, RF Hamman, SL Edelstein, E Barrett-Conner, DA Ehrmann, EA Walker, SE Fowler, DM Nathan, SE Kahn, and Diabetes Prevention Program Research Group, 2005, Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program, *Diabetes*, 54(4):1150-6.
- Lee, WM, 2003, Acute Liver Failure in the United States, *Semin Liver Dis*, 23(3):217-26.
- Lee, WM and JR Senior, 2005, Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions, *Toxicol Pathol*, 33(1):155-64.
- Lewis, JH, 2002, The Rational Use of Potentially Hepatotoxic Medications in Patients with Underlying Liver Disease, *Expert Opin Drug Saf*, 1(2):159-72.
- Lewis, JH, 2006, 'Hy's Law,' the 'Rezulin Rule,' and Other Predictors of Severe Drug-Induced Hepatotoxicity: Putting Risk-Benefit into Perspective, *Pharmacoepidemiol Drug Saf*, 15(4):221-9.
- Moses, PL, B Schroeder, O Alkhatib, N Ferrentino, T Suppan, and SD Lidofsky, 1999, Severe Hepatotoxicity Associated with Bromfenac Sodium, *Am J Gastroenterol*, 94(5):1393-6.

Contains Nonbinding Recommendations

Draft — Not for Implementation

- Navarro, VJ and JR Senior, 2006, Drug-Related Hepatotoxicity, *N Eng J Med*, 354(7):731-9.
- Nolan, CM, SV Goldberg, and SE Buskin, 1999, Hepatotoxicity Associated with Isoniazid Preventative Therapy: A 7-Year Survey from a Public Health Tuberculosis Clinic, *JAMA*, 281(11):1014-8.
- Park, BK, NR Kitteringham, JL Maggs, M Pirmohammed, and DP Williams, 2005, The Role of Metabolic Activation in Drug-Induced Hepatotoxicity, *Annu Rev Pharmacol Toxicol*, 45:177-202.
- Pessayre, D, M Biachara, G Feldmann, C Degott, F Potet, and JP Benhamou, 1979, Perhexiline Maleate-Induced Cirrhosis, *Gastroenterology*, 76(1):170-7.
- Rabkin, JM, MJ Smith, SL Orloff, CL Corless, P Stenzel, and AJ Olyaei, 1999, Fatal Fulminant Hepatitis Associated with Bromfenac Use, *Ann Pharmacother*, 33(9):945-7.
- Reuben, A, 2004, Hy's Law, *Hepatology*, 39(2):574-8.
- Rosner, B, 1995, The Binomial Distribution, in: Rosner B, *Fundamentals of Biostatistics*, pp. 82-5, Duxbury Press, Belmont CA.
- Semino-Mora, C, M Leon-Monzon, and MC Dalakas, 1997, Mitochondrial and Cellular Toxicity Induced by Fialuridine in Human Muscle In Vitro, *Lab Invest*, 76(4):487-95.
- Senior, JR, 2006, How Can 'Hy's Law' Help the Clinician?, *Pharmacoepidemiol Drug Saf*, 15(4):235-9.
- Taggart, HM and JM Alderdice, 1982, Fatal Cholestatic Jaundice in Elderly Patients Taking Benoxaprofen, *Br Med J*, 284(6326):1372.
- Temple, R, 2001, Hepatotoxicity Through the Years: Impact on the FDA, presented 12 February 2001, <http://www.fda.gov/cder/livertox/Presentations/im1389/sld001.htm>.
- Temple, R, 2006, Predicting Serious Hepatotoxicity, *Pharmacoepidemiol Drug Saf*, 15(4):241-3.
- Vella, A, PC deGroen, and SF Dinneen, 1998, Fatal Hepatotoxicity Associated with Troglitazone, *Ann Intern Med*, 129(12):1080.
- Watkins, PB, 2005, Insight into Hepatotoxicity: The Troglitazone Experience, *Hepatology*, 41(2):229-30.
- Zhang, D, TJ Chando, DW Everett, CJ Patten, SS Dehai, and WG Humphreys, 2005, In Vitro Inhibition of Glucuronyltransferases by Atazanavir and Other HIV Protease Inhibitors and the Relationship of this Property to In Vivo Bilirubin Glucuronidation, *Drug Metab Dispos*, 33(11):1729-39.

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 828 Zimmerman, HJ, 1978, Drug-Induced Liver Disease, in: Hepatotoxicity, The Adverse Effects of
829 Drugs and Other Chemicals on the Liver, 1st ed., pp. 351-3, Appleton-Century-Crofts,
830 New York.
831
832 Zimmerman, HJ, 1999, Drug-Induced Liver Disease, in: Hepatotoxicity, The Adverse Effects of
833 Drugs and Other Chemicals on the Liver, 2nd ed., pp. 428-33, Lippincott Williams &
834 Wilkins, Philadelphia.
835

APPENDIX A: ILLUSTRATIVE EXAMPLES OF DILI

Duract (bromfenac)

Bromfenac was a nonsteroidal anti-inflammatory drug (NSAID) studied for both short-term analgesia and long-term arthritis treatment. There was little evidence of hepatotoxicity in the short-term analgesic trials, but during longer term clinical trials in arthritis, ALT elevations >3xULN were seen in 2.8 percent of patients on bromfenac, compared to none in placebo group. Among 1,195 exposed patients, there were two cases in which there was elevated TBL as well as AT elevation in the clinical trial data submitted for review in the NDA. Concerns about possible liver toxicity led to the approval of bromfenac in July 1997 for short-term use only and not for osteoarthritis or rheumatoid arthritis. As an NSAID, however, it was prescribed long-term off-label in arthritic patients, and severe hepatotoxicity emerged. Within 6 months of approval, reports of severe hepatic failure, including two cases requiring liver transplant, were received. All severe cases involved the use of bromfenac for more than 10 days, the maximum duration of treatment recommended in the labeling.

In response, the FDA and the manufacturer strengthened the warnings in the package insert with a boxed warning, and issued a Dear Health Care Professional letter. Despite these efforts, the manufacturer and the FDA continued to receive reports of severe injuries, including reports of death or need for liver transplantation (Moses and Schroeder et al. 1999; Hunter and Johnston et al. 1999; Rabkin and Smith et al. 1999; Fontana and McCashland et al. 1999). Given the availability of other NSAIDs of equal effectiveness and safety, bromfenac was withdrawn from the market in June 1998. The two Hy's Law cases in the long-term-exposed population of about 1,000 subjects during drug development predicted an occurrence of severe hepatotoxicity during chronic use at a rate of about 1/5,000 to 10,000 people. Following approval, rates of acute liver failure for bromfenac were estimated to be in the range of 1/10,000 (Goldkind and Laine 2006).

Rezulin (troglitazone)

Troglitazone was approved by the FDA in January 1997 for the treatment of Type 2 diabetes mellitus. In reviews of the clinical trials of troglitazone conducted before approval there were no cases of liver failure among 2,510 subjects exposed to the drug in the NDA database, but 1.9 percent of troglitazone-treated subjects had ALT >3xULN compared to 0.3 percent of placebo-treated subjects, 1.7 percent had ALT >5xULN, and 0.2 percent (5 subjects) had ALT >30xULN (2 subjects in the last group also experienced jaundice). The median duration of troglitazone therapy before peak ALT elevation was 121 days. In the Diabetes Prevention Trial at the National Institutes of Health (NIH) performed after approval, 4.3 percent of 585 troglitazone-treated subjects had ALT ≥3xULN, 1.5 percent had ALT >8xULN, and 2 subjects had ALT >30xULN, compared to 3.6 percent of subjects with ALT ≥3xULN in the placebo group (Knowler and Hamman et al. 2005). One of the subjects with ALT >30xULN developed liver failure and died, despite receiving a liver transplant. The second subject recovered. These data suggest that the rate of severe liver injury would be about 1 in 3,000 to 10,000.

After marketing, there were numerous reports (Gitlin and Julie et al. 1998; Vella and deGroen et al. 1998; Herrine and Choudary 1999) of acute liver failure associated with troglitazone use, and

Contains Nonbinding Recommendations

Draft — Not for Implementation

four letters were sent to practicing physicians between 1997 and 1999, urging monthly monitoring and careful use. These letters did not significantly affect the monitoring done by physicians, and AT monitoring recommended in the Dear Health Care Professional letters and in the package insert was not regularly performed (Graham and Drinkard et al. 2001). Moreover, an analysis of 94 cases of liver failure reported spontaneously to the FDA showed that the progression from normal hepatic test results to irreversible liver injury occurred in less than a month (the recommended monitoring interval) in 19 patients. The onset of injury began after 3 days to more than 2 years of troglitazone use (Graham and Green et al. 2003a; Graham and Drinkard et al. 2003b). Time from jaundice to hepatic encephalopathy, liver transplantation, or death usually was rapid, averaging 24 days. Troglitazone was withdrawn from the United States market in March 2000, when other agents (rosiglitazone, pioglitazone) with similar efficacy but little or no hepatotoxicity became available.

Apart from constituting another example of the predictive value of evidence of hepatocellular injury accompanied by even two cases of elevated bilirubin, there were other lessons learned from the troglitazone experience: 1) monitoring recommendations, even after several warning letters to all practicing physicians, may not be well followed; and 2) some cases of severe hepatotoxicity occur rapidly, within less than a reasonable and practical recommended interval for monitoring, indicating that monitoring would provide at best only partial protection, even if recommendations were followed. In addition, following the withdrawal of troglitazone, many companies began to search for toxigenomic answers to determining individual susceptibility to DILI, and a national network was funded by NIH in 2003 to study the problem (Watkins 2005).

Exanta (ximelagatran)

Exanta (ximelagatran), an oral anticoagulant (antithrombin), was not marketed in the United States because of hepatotoxicity and other concerns discovered during clinical trials. Issues related to potential liver toxicity of ximelagatran were presented and discussed at an FDA advisory committee meeting in September 2004 (He 2004). During short-term clinical trials of the drug for prevention of thromboembolic complications after joint replacement surgical procedures, there was no increased rate of transaminase elevations in the ximelagatran group compared to the enoxaparin-warfarin group, and no serious hepatotoxicity was seen. But in longer-term (>35 days) trials in patients with chronic atrial fibrillation to prevent embolic or thrombotic strokes, an increase in ALT >3xULN occurred in 7.6 percent of 6,948 patients compared to 1.1 percent of patients receiving warfarin treatment; and 1.5 percent of ximelagatran-treated patients had ALT >10xULN.

Increases in AT typically occurred 1 to 6 months after the initiation of ximelagatran administration with peak levels within 2 to 3 months post-randomization. Among the 531 ximelagatran patients with ALT >3xULN, 39 percent completed the study on treatment, while 61 percent discontinued the drug. Almost all patients with ALT >3xULN returned to <2xULN whether the drug was stopped or not, although the return to normal was faster if ximelagatran was stopped. Of 18 patients who resumed drug after ALT returned to normal, only 2 had elevations recur. Concomitant elevations of ALT >3xULN and bilirubin >2xULN were observed in 37 of about 7,000 patients, at least 13 of whom had no alternative explanation for the concomitant ALT and bilirubin elevation. Nine of the 37 patients died, but the deaths were not

Contains Nonbinding Recommendations

Draft — Not for Implementation

928 clearly hepatotoxicity-related in most cases. Only one autopsy was done and it showed a small,
929 friable and diffusely mottled liver suggestive of severe diffuse hepatic necrosis, but liver failure
930 from ximelagatran might have contributed to some of the other deaths (He 2004; Lewis 2006;
931 Kaplowitz 2006; Senior 2006; Temple 2006). Because severe hepatotoxicity was observed in an
932 orthopedic surgery trial in an extended treatment of 35 days, Exanta was withdrawn in February
933 2006 from the 22 countries in which it had been approved, and further development in the United
934 States was abandoned.

935
936 Again, short-term tolerance of ximelagatran, with resolution of even substantial elevations of
937 ALT in most cases did not predict long-term safety. The relatively high rate of Hy's Law cases,
938 about 0.2 percent or 1/500 (13 cases among 7,000 exposed patients), predicted the occurrence of
939 severe hepatotoxicity, at a rate of about 1/5,000 (10 percent of the rate of Hy's Law cases). In
940 fact, at least one death occurred among the 7,000 exposed patients subsequent liver toxicity,
941 further supporting such an estimate.
942